Abstract
Sequencing technologies have allowed us to characterize highly heterogeneous molecular landscape of breast cancer with unprecedented details. Tremendous breakthroughs have been made in unraveling contributory role of signaling pathways in breast cancer development and progression. It is becoming progressively more understandable that deregulation of spatio-temporally controlled pathways underlie development of resistance against different drugs. TRAIL mediated signaling has attracted considerable appreciation because of its characteristically unique ability to target cancer cells while leaving normal cells intact. Discovery of TRAIL was considered as a paradigm shift in molecular oncology because of its conspicuous ability to selectively target cancer cells. There was an exponential growth in the number of high-quality reports which highlighted cancer targeting ability of TRAIL and scientists worked on the development of TRAIL-based therapeutics and death receptor targeting agonistic antibodies to treat cancer. However, later studies challenged simplistic view related to tumor targeting ability of TRAIL. Detailed mechanistic insights revealed that overexpression of anti-apoptotic proteins, inactivation of pro-apoptotic proteins and downregulation of death receptors were instrumental in impairing apoptosis in cancer cells. Therefore researchers started to give attention to identification of methodologies and strategies to overcome the stumbling blocks associated with TRAIL-based therapeutics. Subsequent studies gave us a clear picture of signaling cascade of TRAIL and how deregulation of different proteins abrogated apoptosis. In this chapter we have attempted to provide an overview of the TRAIL induced signaling, list of proteins frequently deregulated and modern approaches to strategically restore apoptosis in TRAIL–resistant breast cancers.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Zardavas D, Irrthum A, Swanton C, Piccart M (2015) Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 12(7):381–394. https://doi.org/10.1038/nrclinonc.2015.73
Kwa M, Makris A, Esteva FJ (2017) Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol 14(10):595–610. https://doi.org/10.1038/nrclinonc.2017.74
Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718–730. https://doi.org/10.1038/nrclinonc.2009.166
Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, Zhou M (2010) Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol 6(9):485–493. https://doi.org/10.1038/nrendo.2010.92
Lee A, Djamgoz MBA (2018) Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62:110–122. https://doi.org/10.1016/j.ctrv.2017.11.003
Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14(5):359–372
von Karstedt S, Montinaro A, Walczak H (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer 17(6):352–366. https://doi.org/10.1038/nrc.2017.28
de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L (2016) Onto better TRAILs for cancer treatment. Cell Death Differ 23(5):733–747. https://doi.org/10.1038/cdd.2015.174
Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, Stremmel W, Sinn HP, Walczak H (2009) Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 87(10):995–1007. https://doi.org/10.1007/s00109-009-0510-z
Labovsky V, Martinez LM, Davies KM, de Luján Calcagno M, García-Rivello H, Wernicke A, Feldman L, Matas A, Giorello MB, Borzone FR, Choi H, Howard SC, Chasseing NA (2017) Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer 17(1):280. https://doi.org/10.1186/s12885-017-3259-8
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S (2005) Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5:54
Ruiz de Almodóvar C, Ruiz-Ruiz C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A (2004) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J Biol Chem 279(6):4093–4101
Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL (2017) A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Mol Cancer Res 15(4):382–394. https://doi.org/10.1158/1541-7786.MCR-16-0234. Epub 2017 Jan 20
Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW (2016) Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ 23(11):1886–1896. https://doi.org/10.1038/cdd.2016.92
Mauro-Lizcano M, López-Rivas A (2018) Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells. Cell Death Dis 9(2):205. https://doi.org/10.1038/s41419-018-0263-0.
Strekalova E, Malin D, Good DM, Cryns VL (2015) Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL Receptor-2 expression. Clin Cancer Res 21(12):2780–2791. https://doi.org/10.1158/1078-0432.CCR-14-2792
Wang S, Shao M, Zhong Z, Wang A, Cao J, Lu Y, Wang Y, Zhang J (2017) Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv 24(1):1791–1800. https://doi.org/10.1080/10717544.2017.1406558
Wang S, Xu Y, Li C, Tao H, Wang A, Sun C, Zhong Z, Wu X, Li P, Wang Y (2018. pii: S0278-6915(18)30102-9) Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings. Food Chem Toxicol. https://doi.org/10.1016/j.fct.2018.02.037
Song W, Yan CY, Zhou QQ, Zhen LL (2017) Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. Biomed Pharmacother 89:845–856. https://doi.org/10.1016/j.biopha.2017.01.062
Sant DW, Mustafi S, Gustafson CB, Chen J, Slingerland JM, Wang G (2018) Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. Sci Rep 8(1):5306. https://doi.org/10.1038/s41598-018-23714-7
Piggott L, da Silva AM, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Piva M, Vivanco MD, Morris C, Alchami FS, Young P, Barrett-Lee PJ, Clarke RB, Gee JM, Clarkson R (2018. pii: clincanres.1381.2017) Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-1381
Jablonowski LJ, Conover D, Teraphongphom NT, Wheatley MA (2018) Manipulating multifaceted microbubble shell composition to target both TRAIL-sensitive and resistant cells. J Biomed Mater Res A. https://doi.org/10.1002/jbm.a.36389
Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O (2017) TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. Oncotarget 8(6):9974–9985. https://doi.org/10.18632/oncotarget.14285
Shlyakhtina Y, Pavet V, Gronemeyer H (2017) Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis 8(8):e3025. https://doi.org/10.1038/cddis.2017.423
Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jonat W, Becker T, Glüer CC, Zöller M, Kalthoff H, Schem C, Trauzold A (2015) TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model. Oncotarget 6(11):9502–9516
Wang D, Liu D, Gao J, Liu M, Liu S, Jiang M, Liu Y, Zheng D (2013) TRAIL-induced miR-146a expression suppresses CXCR4-mediated human breast cancer migration. FEBS J 280(14):3340–3353. https://doi.org/10.1111/febs.12323
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yin, N., Yi, L., Khalid, S., Ozbey, U., Sabitaliyevich, U.Y., Farooqi, A.A. (2019). TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome Drug Resistance. In: Ahmad, A. (eds) Breast Cancer Metastasis and Drug Resistance. Advances in Experimental Medicine and Biology, vol 1152. Springer, Cham. https://doi.org/10.1007/978-3-030-20301-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-20301-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-20300-9
Online ISBN: 978-3-030-20301-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)